Plain-English translation of NCT02943590 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Heart failure research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tested whether , a medication commonly used to lower cholesterol, could protect the hearts of patients receiving doxorubicin chemotherapy for blood cancers like lymphoma. Doxorubicin can damage the heart in some patients, potentially leading to heart failure. Researchers wanted to see if this medication could reduce that risk.
Doxorubicin is an effective chemotherapy drug, but it can damage the heart muscle and lead to heart failure in some patients. This trial was designed to find out whether starting this medication before and during chemotherapy could protect the heart and prevent these serious side effects.
Participants received either or a placebo pill to take once daily by mouth during their chemotherapy treatment. The research team monitored heart health using heart imaging tests (an echocardiogram and an MRI scan of the heart), blood tests, and stress testing to determine whether the medication protected the heart from chemotherapy-related damage.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States
Canada